In-vivo Drug Evaluation
NHRF/ICB will provide access to infrastructures and expertise on established models relevant for preclinical evaluation of drugs/therapeutics on cancer, using xeno-transplants (including Patient Derived Xenografts-PDX) and ex-vivo organoid/spheroid cultures (including Patient Derived Spheroids-PDS). Evaluation of the predictive capacity of PDS and PDX to the therapeutic response of the original tumor will be performed. Further, development of novel rational combinatorial therapeutic protocols of anti-cancer drugs at the preclinical stage for each individual tumor will be performed. This is expected to provide oncologists with additional evidence for the preclinical individual tumor vulnerability, which may be later be translated to efficient therapies.